An overview of the utility of prasugrel hydrochloride as a treatment option for ischemic stroke

References

• Khanevski AN, Bjerkreim AT, Novotny V, et al. NOR-STROKE study group. Recurrent ischemic stroke: incidence, predictors, and impact on mortality. Acta Neurol Scand. 2019;140(1):3–8. doi: 10.1111/ane.13093
   PubMed Web of Science ®Google Scholar
• Bangad A, Abbasi M, de Havenon A. Secondary ischemic stroke prevention. Neurotherapeutics. 2023;20(3):721–731. doi: 10.1007/s13311-023-01352-w
   PubMed Web of Science ®Google Scholar
• Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a Guideline from the American Heart Association/American stroke Association. Stroke. 2021;52(7):e364–e467. doi: 10.1161/STR.0000000000000375
   PubMed Web of Science ®Google Scholar
• Dawson J, Béjot Y, Christensen LM, et al. European stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022;7(3):I–II. doi: 10.1177/23969873221100032
   Web of Science ®Google Scholar
• Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–19. doi: 10.1056/NEJMoa1215340
   PubMed Web of Science ®Google Scholar
• Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215–225. doi: 10.1056/NEJMoa1800410
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Denison H, et al. THALES investigators. Ticagrelor and aspirin or aspirin Alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207–217. doi: 10.1056/NEJMoa1916870
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482
   PubMed Web of Science ®Google Scholar
• EFFIENT package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022307s002lbl.pdf. Accessed 2023 jun 8.
   Google Scholar
• Kitazono T, Kamouchi M, Matsumaru Y, et al. Efficacy and safety of prasugrel vs clopidogrel in thrombotic stroke patients with risk factors for ischemic stroke recurrence: a double-blind, phase III study (PRASTRO-III). J Atheroscler Thromb. 2023;30(3):222–236. doi: 10.5551/jat.63473
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–1717. doi: 10.1056/NEJMoa060989
   PubMed Web of Science ®Google Scholar
• Benavente OR, Hart RG, McClure LA, et al. The SPS3 investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817–825.
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–337. doi: 10.1016/S0140-6736(04)16721-4
   PubMed Web of Science ®Google Scholar
• Johnston SC, Elm JJ, Easton JD, et al. POINT and neurological emergencies treatment trials network investigators. Time course for benefit and risk of clopidogrel and aspirin after acute transient ischemic attack and minor ischemic stroke. Circulation. 2019;140(8):658–664. doi: 10.1161/CIRCULATIONAHA.119.040713
   PubMed Web of Science ®Google Scholar
• Wang Y, Pan Y, Li H, et al. Time Course for benefit and risk of ticagrelor and aspirin in acute ischemic stroke or transient ischemic attack. Neurology. 2022;99(1):e46–e54. doi: 10.1212/WNL.0000000000200355
   PubMed Web of Science ®Google Scholar
• Wang Y, Meng X, Wang A, et al. CHANCE-2 investigators. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520–2530. doi: 10.1056/NEJMoa2111749
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482
   PubMed Web of Science ®Google Scholar
• Hira RS, Kennedy K, Jneid H, et al. Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;63(25):2876–2877. doi: 10.1016/j.jacc.2014.04.011
   PubMed Web of Science ®Google Scholar
• Sandhu A, Seth M, Dixon S, et al. Contemporary use of prasugrel in clinical practice: insights from the Blue cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Qual Outcomes. 2013;6(3):293–298. doi: 10.1161/CIRCOUTCOMES.111.000060
   PubMed Web of Science ®Google Scholar
• Chin CT, Neely B, Magnus Ohman E, et al. Time-varying effects of prasugrel versus clopidogrel on the long-term risks of stroke after acute coronary syndromes: results from the TRILOGY ACS trial. Stroke. 2016;47(4):1135–1139. doi: 10.1161/STROKEAHA.115.012454
   PubMed Web of Science ®Google Scholar
• Nagao T, Toyoda K, Kitagawa K, et al. A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial – PRASTRO-I trial. Expert Opin Pharmacother. 2018;19(6):529–535. doi: 10.1080/14656566.2018.1444029.
   PubMed Web of Science ®Google Scholar
• Ogawa A, Toyoda K, Kitagawa K, et al. Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I). Lancet Neurol. 2019;18(3):238–247. doi: 10.1016/S1474-4422(18)30449-6
   PubMed Web of Science ®Google Scholar
• Kitazono T, Toyoda K, Kitagawa K, et al. Efficacy and safety of prasugrel by stroke subtype: a sub-analysis of the PRASTRO-I randomized controlled trial. J Atheroscler Thromb. 2021;28(2):169–180. doi: 10.5551/jat.56093
   PubMed Web of Science ®Google Scholar
• Amarenco P, Albers GW, Denison H, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(4):301–310. doi: 10.1016/S1474-4422(17)30038-8
   PubMed Web of Science ®Google Scholar
• Liu L, Wong KSL, Leng X, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85(13):1154–62. doi: 10.1212/WNL.0000000000001972
   PubMed Web of Science ®Google Scholar
• Investigators SPS3, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817–25.
   PubMed Web of Science ®Google Scholar
• Toyoda K, Yamagami H, Kitagawa K, et al. Blood pressure Level and variability during long-term prasugrel or clopidogrel medication after stroke: PRASTRO-I. Stroke. 2021;52(4):1234–1243. doi: 10.1161/STROKEAHA.120.032824
   PubMed Web of Science ®Google Scholar
• Kitagawa K, Toyoda K, Kitazono T, et al. Safety and efficacy of prasugrel in Elderly/low body weight Japanese patients with ischemic stroke: randomized PRASTRO-II. Cerebrovasc Dis. 2020;49(2):152–159. doi: 10.1159/000506825
   PubMed Web of Science ®Google Scholar
• Ohkubo K, Fujimoto Y, Iwata Y, et al. Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. Heart Vessels. 2014;29(1):1–6. doi: 10.1007/s00380-012-0318-6
   PubMed Web of Science ®Google Scholar
• Kitazono T, Kamouchi M, Matsumaru Y, et al. Comparison of prasugrel and clopidogrel in thrombotic stroke patients with risk factors for ischemic stroke recurrence: an Integrated analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III. Cerebrovasc Dis. 2023 Apr;3:1–10. doi: 10.1159/000529149
   Google Scholar
• EFIENT®(package insert). Tokyo Japan: Daiichi Sankyo Co. Ltd.; 2021 (ver.3). Available from:https://www.info.pmda.go.jp/go/pack/3399009F1020120/view=frame&style=XML&lang=ja
   Google Scholar
• Daiichi Sankyo submits supplemental application in Japan for approval of partial changes related to additional indication for the antiplatelet agent, prasugrel hydrochloride. https://www.daiichisankyo.com/media/press_release/detail/index_4103.html
   Google Scholar
• Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012;125(10):1276–1287. discussion 1287. doi: 10.1161/CIRCULATIONAHA.111.031195
   PubMed Web of Science ®Google Scholar
• Kim HK, Tantry US, Smith SJ, et al. The East Asian Paradox: an updated position statement on the challenges to the Current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2021;121:422–432.
   PubMed Web of Science ®Google Scholar